Fourth quarter revenue was impacted by higher deferrals of infusions into We remain committed to maximizing value for stakeholders and look forward to sharing more detail during our earnings call next month. This information is based on currently available information. Final results may therefore vary from these estimates. ABECMA is a B-cell maturation antigen BCMA -directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
Out of the 20 deaths that occurred prior to ABECMA infusion, 15 occurred from disease progression, 3 occurred from adverse events and 2 occurred from unknown causes. Out of the 25 deaths that occurred after ABECMA infusion, 10 occurred from disease progression, 11 occurred from adverse events, and 4 occurred from unknown causes. The median time-to-onset of CRS, any grade, was 1 day range: 1 to 27 days , and the median duration of CRS was 5 days range: 1 to 63 days.
Identify CRS based on clinical presentation. Evaluate for and treat other causes of fever, hypoxia, and hypotension.
Almost all patients who received corticosteroids for CRS also received tocilizumab. Counsel patients to seek immediate medical attention should signs or symptoms of CRS occur at any time.
The median time to onset of neurotoxicity was 2 days range: 1 to days. The median duration of CAR T cell-associated neurotoxicity was 8 days range: 1 to days in all patients including those with ongoing neurologic events at the time of death or data cut off. In KarMMa, one patient had ongoing Grade 2 neurotoxicity at the time of death.
